ClinicalTrials.gg
CompletedNCT02334787Updated Oct 3, 2016Results posted

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

A Phase 1 interventional study of 0.3% OPA-15406 Ointment and 1% OPA-15406 Ointment in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-03.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
15th of 16
32 · median 177
Started
2015
the only one that year
Phase 1
2 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 20 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese healthy adult male subjects.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • = Body weight (kg) / [Height (m)]2: at least 18.5 and less than 25.0
  • Judged by the investigator or subinvestigator to be healthy based on test results at screening and prior to administration on Day 1 of the treatment period

Exclusion criteria

Exclusion Criteria:

  • Findings (sunburn, abrasions, tattoos, etc) on the back that affect the evaluation of the safety of the skin
  • Judged by the investigator or subinvestigator as inappropriate to participate in this trial for any other reasons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    0.3% OPA-15406 in a single administration period

    32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.

    Drug: 0.3% OPA-15406 Ointment

  • Experimental
    1% OPA-15406 in a single administration period

    32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.

    Drug: 1% OPA-15406 Ointment

  • Experimental
    3% OPA-15406 in a single administration period

    32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.

    Drug: 3% OPA-15406 Ointment

  • Placebo comparator
    Placebo in a single administration period

    32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.

    Drug: Placebo Ointment

  • Experimental
    0.3% OPA-15406 in the multiple administration period

    In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.

    Drug: 0.3% OPA-15406 Ointment

  • Experimental
    1% OPA-15406 in the multiple administration period

    In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.

    Drug: 1% OPA-15406 Ointment

  • Experimental
    3% OPA-15406 in the multiple administration period

    In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.

    Drug: 3% OPA-15406 Ointment

  • Experimental
    Placebo in the multiple administration period

    In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.

    Drug: Placebo Ointment

Interventions

  • 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.

    Also known as: OPA-15406 Ointment

  • 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose

    Also known as: OPA-15406 Ointment

  • 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.

    Also known as: OPA-15406 Ointment

  • DrugPlacebo Ointment

    32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.

06

What researchers measure

Primary outcomes

  1. Cmax of OPA-15406 in a Single Administration Period

    We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.

    Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr

  2. Cmax of OPA-15406 in the Multiple Administration Period

    We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.

    Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14

Secondary outcomes

  1. AUC12h of OPA-15406 in a Single Administration Period

    We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.

    Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs

  2. AUC12h of OPA-15406 in the Multiple Administration Period

    We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.

    Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14

07

Results

Posted Oct 3, 2016

Participant flow

Participant flow — Overall Study
Milestone0.3% OPA-15406 Ointment1% OPA-15406 Ointment3% OPA-15406 OintmentPlacebo
Started8888
Completed8888
Not completed0000

Outcome measures

PrimaryCmax of OPA-15406 in a Single Administration Period

We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.

Time frame:
Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr
Reported as:
Mean · ng/mL
Cmax of OPA-15406 in a Single Administration Period
ng/mL0.3% OPA-15406 Ointment in a Single Administration Period1% OPA-15406 Ointment in a Single Administration Period3% OPA-15406 Ointment in a Single Administration Period
Cmax of OPA-15406 in a Single Administration Period0.508 ± 0.3040.838 ± 0.5311.61 ± 0.835
PrimaryCmax of OPA-15406 in the Multiple Administration Period

We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.

Time frame:
Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14
Reported as:
Mean · ng/mL
Cmax of OPA-15406 in the Multiple Administration Period
ng/mL0.3 % OPA-15406 Ointment in the Multiple Administration Period1 % OPA-15406 Ointment in the Multiple Administration Period3% OPA-15406 Ointment in the Multiple Administration Period
Cmax of OPA-15406 in the Multiple Administration Period0.506 ± 0.3480.795 ± 0.2081.65 ± 0.462
SecondaryAUC12h of OPA-15406 in a Single Administration Period

We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.

Time frame:
Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs
Reported as:
Mean · ng・h/mL
AUC12h of OPA-15406 in a Single Administration Period
ng・h/mL0.3% OPA-15406 Ointment in a Single Administration Period1% OPA-15406 Ointment in a Single Administration Period3% OPA-15406 Ointment in a Single Administration Period
AUC12h of OPA-15406 in a Single Administration Period3.74 ± 2.326.42 ± 4.8611.2 ± 6.24
SecondaryAUC12h of OPA-15406 in the Multiple Administration Period

We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.

Time frame:
Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14
Reported as:
Mean · ng・h/mL
AUC12h of OPA-15406 in the Multiple Administration Period
ng・h/mL0.3 % OPA-15406 Ointment in the Multiple Administration Period1 % OPA-15406 Ointment in the Multiple Administration Period3% OPA-15406 Ointment in the Multiple Administration Period
AUC12h of OPA-15406 in the Multiple Administration Period4.65 ± 3.077.84 ± 1.7816.6 ± 4.99

Adverse events

Collected over A single administration: From date of informed consent to 48 hours post dose The multiple administration: From date of assigned IMP twice daily to 16 days post dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.3 % OPA-15406 Ointment in a Single Administration Period—0/8 (0%)0/8 (0%)
1% OPA-15406 Ointment in a Single Administaration Period—0/8 (0%)0/8 (0%)
3% OPA-15406 Ointment in a Single Administaration Period—0/8 (0%)0/8 (0%)
Placebo in a Single Adminstaration Period—0/8 (0%)0/8 (0%)
0.3 % OPA-15406 Ointment in the Multiple Administration Period—0/8 (0%)0/8 (0%)
1 % OPA-15406 Ointment in the Multiple Administration Period—0/8 (0%)0/8 (0%)
3 % OPA-15406 Ointment in the Multiple Administration Period—0/8 (0%)0/8 (0%)
Placebo Ointment in the Multiple Administration Period—0/8 (0%)0/8 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)0.3% OPA-15406 Ointment1% OPA-15406 Ointment3% OPA-15406 OintmentPlaceboTotal
<=18 years00000
Between 18 and 65 years888832
>=65 years00000
Age, Continuous
Age, Continuous(years)0.3% OPA-15406 Ointment1% OPA-15406 Ointment3% OPA-15406 OintmentPlaceboTotal
Mean31.9 ± 7.228.3 ± 7.630.5 ± 6.729.5 ± 6.330.0 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)0.3% OPA-15406 Ointment1% OPA-15406 Ointment3% OPA-15406 OintmentPlaceboTotal
Female00000
Male888832
Region of Enrollment
Region of Enrollment(participants)0.3% OPA-15406 Ointment1% OPA-15406 Ointment3% OPA-15406 OintmentPlaceboTotal
Japan888832
08

Study locations

1 site
  • Kanto Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2015
First posted
Jan 8, 2015
Start
Jan 2015
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Oct 3, 2016
Last update
Oct 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02334787
Responsible party
Sponsor
First posted
Jan 8, 2015
Start date
Jan 2015
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Oct 3, 2016
Last update
Oct 3, 2016

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion